
HEALTHCARE CONFERENCE 2026




BELL POTTER

ASX

Day 1: Tuesday 17 November

8:25AM	WELCOME & HOUSEKEEPING	
8:30AM	PRO MEDICUS (PME)	Session 1
9:00AM	MACH7 TECHNOLOGIES (M7T)	
9:30AM	ALCIDION (ALC)	
10:00AM	AUSTCO HEALTHCARE (AHC)	
10:25AM	MORNING TEA	
10:30AM	4DMEDICAL (4DX)	Session 2
11:00AM	ARTRYA (AYA)	
11:30AM	ECHO IQ (EIQ)	
12:00PM	CRYOSITE (CTE)	
12:30PM	LUNCH	
1:00PM	VITRAFY LIFE SCIENCES (VFY)	Session 3
1:30PM	TRAJAN SCIENTIFIC AND MEDICAL (TRJ)	
2:00PM	CYCLOPHARM (CYC)	
2:30PM	EMVISION MEDICAL DEVICES (EMV)	
2:55PM	AFTERNOON TEA	
3:00PM	NOVA EYE MEDICAL (EYE)	Session 4
3:30PM	IMPEDIMED (IPD)	
4:00PM	PACIFIC EDGE (PEB)	
4:30PM	LUMOS DIAGNOSTICS (LDX)	
4:55PM	WRAP UP	

HEALTHCARE CONFERENCE 2026




BELL POTTER

ASX

Day 2: Wednesday 18 November


8:25AM	WELCOME & HOUSEKEEPING	
8:30AM	CLARITY PHARMACEUTICALS (CU6)	Session 1
9:00AM	TELIX PHARMACEUTICALS (TLX)	
9:30AM	RADIOPHARM THERANOSTICS (RAD)	
10:00AM	EBR SYSTEMS (EBR)	
10:25AM	MORNING TEA	
10:30AM	SALUDA MEDICAL (SLD)	Session 2
11:00AM	POLYACTIVA PTY LTD	
11:30AM	PHARMX (PHX)	
12:00PM	BIOME (BIO)	
12:30PM	LUNCH	
1:00PM	SOMNOMED (SOM)	Session 3
1:30PM	NANOSONICS (NAN)	
2:00PM	OPTISCAN IMAGING (OIL)	
2:30PM	COGSTATE (CGS)	
2:55PM	AFTERNOON TEA	
3:00PM	ORTHOCELL (OCC)	Session 4
3:30PM	AVITA MEDICAL (AVH)	
4:00PM	POLYNOVO (PNV)	
4:30PM	AROA BIOSURGERY (ARX)	
4:55PM	WRAP UP	



Day 3: Thursday 19 November

8:25AM	WELCOME & HOUSEKEEPING	
8:30AM	LTR PHARMA (LTP)	Session 1
9:00AM	NEURIZON THERAPEUTICS (NUZ)	
9:30AM	MESOBLAST (MSB)	
10:00AM	NYRADA (NYR)	
10:25AM	MORNING TEA	
10:30AM	DOCTOR CARE ANYWHERE (DOC)	Session 2
11:00AM	PYC THERAPEUTICS (PYC)	
11:30AM	NEUREN PHARMACEUTICALS (NEU)	
12:00PM	ALTERITY THERAPEUTICS (ATH)	
12:30PM	ONCOSIL MEDICAL (OSL)	
1:00PM	AMPLIA THERAPEUTICS (ATX)	Session 3
1:30PM	RACURA ONCOLOGY (RAC)	
2:00PM	SYNTARA (SNT)	
2:30PM	IMMUTEP (IMM)	
2:55PM	AFTERNOON TEA	
3:00PM	IMMVIRX PTY LTD	Session 4
3:30PM	QBIOTICS	
4:00PM	MAYNE PHARMA (MYX)	
4:30PM	BLS PHARMACEUTICALS (BLS)	
4:55PM	WRAP UP	

HEALTHCARE CONFERENCE 2026



BELL POTTER

ASX

Day 1: Tuesday 17 November

8:30AM PRO MEDICUS (PME)

Pro Medicus is a leading global provider of enterprise imaging and healthcare informatics solutions. Its RIS, PACS and advanced visualization platforms help healthcare providers improve workflow efficiency, access medical data, enhance clinical decision-making and deliver better patient outcomes through scalable, integrated technology.

9:00AM MACH7 TECHNOLOGIES (M7T)


Mach7 Technologies provides enterprise imaging software that helps healthcare organisations manage, access and share diagnostic imaging data across complex environments. Mach7's platform includes a Vendor Neutral Archive (VNA), eUnity Viewer and suite of Flamingo modules, expanding capabilities across workflow, interoperability and data management to support a more complete view of the patient record.

9:30AM ALCIDION (ALC)

Alcidion transforms healthcare through proactive, smart and intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations worldwide. With more than 25 years of healthcare experience, Alcidion combines leading technology with deep healthcare expertise to deliver solutions that make health better for everyone.

10:00AM AUSTCO HEALTHCARE (AHC)

Austco Healthcare provides clinical communication and workflow technology to hospitals and aged care. Its Tacera nurse call platform, Pulse Mobile and real-time location solutions support more than 5,000 healthcare facilities in over 60 countries. In FY26, revenue grew 15.8% to $94.2 million and EBITDA 14.0% to $14.9 million.



Day 1: Tuesday 17 November

10:30AM 4DMEDICAL (4DX)

4DMedical is a global medtech leader advancing respiratory and cardiothoracic care through AI-enabled imaging. Led by CT:VQ™, its breakthrough non-contrast ventilation and perfusion technology, the company is deployed in leading U.S. academic medical centers, expanding across Europe, and creating a comprehensive platform spanning lung imaging, diagnosis, and care.

11:00AM ARTRYA (AYA)

Artrya is a medical technology company transforming the diagnosis and management of coronary artery disease. Its FDA-cleared Salix® platform uses AI to analyse cardiac CT scans in real time, helping clinicians identify disease, streamline clinical workflows and deliver faster, more informed patient care.


11:30AM ECHO IQ (EIQ)

Echo IQ develops AI-driven innovations to help provide fast, precise insights into structural heart damage. Our solutions are designed to optimize efficiency, consistency, throughput, and turnaround time. By using the same echo measurements already collected, we deliver measurement-based decision support without image analysis.

12:00PM CRYOSITE (CTE)

Cryosite is world-class specialist providing outsourced clinical trial and biological depot services since 2000. Our expert team of scientists and clinical trials specialists manages importation, storage, distribution, and reverse logistics for ambient, cold, frozen, ultra-frozen, and liquid nitrogen products. We deliver professional, reliable and compliant services with ethical, responsive support tailored to client needs.

HEALTHCARE CONFERENCE 2026



BELL POTTER

ASX

Day 1: Tuesday 17 November

1:00PM VITRAFY LIFE SCIENCES (VFY)

Vitrafy provides an integrated cryopreservation solution combining its proprietary Guardion smart hardware and LifeChain™ cloud-based software platform. The system preserves biomaterial quality and integrity throughout storage, helping organisations safeguard sensitive biological samples while improving reliability, traceability and operational efficiency across a range of life sciences applications.

1:30PM TRAJAN (TRJ)

Trajan develops and manufactures analytical and life sciences products and devices. It was founded to enable science that benefits people by enriching personal health through scientific tools and solutions. Globally, Trajan employs approximately 600 people, with nine manufacturing and operations sites across the US, Australia, Europe and Asia.


2:00PM CYCLOPHARM (CYC)

Cyclomedica is a global nuclear medicine and molecular imaging provider, renowned for Technegas®, its groundbreaking technology that is revolutionising pulmonary diagnostic imaging and patient management across the world.

2:30PM EMVISION (EMV)

EMVision develops portable, non-ionising brain scanners that enable stroke diagnosis at the point of care. Its pivotal trial supporting FDA De Novo clearance has achieved key enrolment milestones across leading US and Australian stroke centres. Backed by strong funding, strategic investors and clinical partnerships, EMVision is advancing stroke care.

HEALTHCARE CONFERENCE 2026



BELL POTTER

ASX

Day 1: Tuesday 17 November

3:00PM NOVA EYE MEDICAL (EYE)

Nova Eye Medical designs manufactures and sells surgical devices for glaucoma in the USA and Europe. The global interventional market is large and growing. EYE has trailing annual revenues of $35 million that are growing at 25% p.a. and is EBITDA positive.

3:30PM IMPEDIMED (IPD)


ImpediMed is a global medical technology company specialising in bioimpedance spectroscopy (BIS) for non-invasive assessment of fluid status and body composition. The FDA-cleared SOZO® Digital Health Platform platform and L-Dex® technology are the standard for early detection and management of breast cancer-related lymphoedema, and its BodyComp™ Analysis supports cancer survivorship, exercise oncology, and wellness programs.

4:00PM PACIFIC EDGE (PEB)

With its Cxbladder genomic urine tests included in leading US clinical guidelines, Pacific Edge is a global cancer diagnostics company at the forefront of non-invasive bladder cancer detection and surveillance. Cxbladder tests help clinicians prioritize clinical resource and optimize workflow, while giving patients the best experience possible.

4:30PM LUMOS DIAGNOSTICS (LDX)

Lumos Diagnostics develops, manufactures and commercialises point-of-care diagnostic technologies that deliver real-time clinical insights. Its business comprises proprietary diagnostic products, including FebriDx®, and commercial contract development and manufacturing services, supporting healthcare providers and partners with rapid, accessible and reliable diagnostic solutions worldwide.



Day 2: Wednesday 18 November

8:30AM CLARITY PHARMACEUTICALS (CU6)

Clarity is a clinical-stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics (TCTs) based on its SAR Technology Platform for the treatment of cancers.

9:00AM TELIX PHARMACEUTICALS (TLX)


Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

9:30AM RADIOPHARM THERANOSTICS (RAD)

Radiopharm Theranostics is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals. Our proprietary platforms span across nanobodies, antibodies, small molecules and peptides, all purposefully designed to address significant unmet needs in oncology.

10:00AM EBR SYSTEMS (EBR)

EBR Systems is an ASX listed, California-based company that has developed the WiSE® System, the world's only leadless pacemaker able to pace the left-ventricular for the treatment of heart failure without requiring the use of leads. EBR has the foundations in place to become a high growth medical device company.



Day 2: Wednesday 18 November

10:30AM SALUDA MEDICAL (SLD)

Saluda Medical develops closed-loop neuromodulation technologies for chronic neurological conditions. Its proprietary platform measures neural responses and automatically adjusts therapy in real time. The company's flagship product, Evoke®, delivers spinal cord stimulation for chronic neuropathic pain, improving treatment effectiveness while reducing patient and clinician burden.

11:00AM POLYACTIVA

PolyActiva is an innovative global clinical-stage ophthalmology company with a unique proprietary polymeric prodrug technology that enables site-specific, precise and controlled drug delivery to the eye, replacing the need for eye drops or frequent injections to treat chronic eye diseases. PolyActiva's lead product is currently in a Phase 2b clinical trial in the USA.


11:30AM PHARMX (PHX)

Pharmx is a leading innovator in the ANZ pharmacy sector, dedicated to making a difference to healthcare by reimagining how the industry connects. As the critical infrastructure provider at the centre of the pharmacy network, Pharmx drives growth by connecting the industry, streamlining inventory management, advancing order management and enabling smarter business decisions through data-led solutions.

12:00PM BIOME AUSTRALIA (BIO)

Biome Australia develops, commercialises and markets innovative, evidence-based live biotherapeutics and complementary medicines with clinically proven health benefits. It aims to prevent disease, improve health outcomes and quality of life, and make its products accessible to all.

HEALTHCARE CONFERENCE 2026



BELL POTTER

ASX

Day 2: Wednesday 18 November

1:00PM SOMNOMED (SOM)

Somnomed is an Australian scale up that manufactures and markets oral appliances for the treatment of sleep apnoea. It has delivered over 1million products to consumers around the world over the last 20 years and is the market leader globally.

1:30PM NANOSONICS (NAN)


Nanosonics is a global leader in automated infection prevention solutions for medical device reprocessing. Its flagship trophon® technology has established a new standard for the high-level disinfection of ultrasound probes and helps protect more than 31 million patients each year. Building on this expertise, Nanosonics is advancing the CORIS® System, a groundbreaking automated technology for flexible endoscope cleaning, into commercialisation.

2:00PM OPTISCAN IMAGING (OIL)

Optiscan Imaging Ltd is a commercial-stage medical technology company developing digital pathology and precision surgery solutions. Its patented endomicroscopy technology enables live, non-destructive, single-cell imaging for real-time cancer diagnosis and surgical guidance. Optiscan targets growing digital health and robotic surgery markets, improving clinical decision-making and patient outcomes.

2:30PM COGSTATE (CGS)

Cogstate is a science-led CNS clinical trial endpoint leader, combining validated digital assessments, scientific expertise and technology-enabled services to improve data quality, strengthen endpoint integrity and deliver clearer trial signals. Its scalable platform supports pharmaceutical sponsors across complex CNS indications, positioning Cogstate to advance brain health research and capture growing demand.



Day 2: Wednesday 18 November

3:00PM ORTHOCELL (OCC)

Orthocell is a regenerative medicine company that helps surgeons maximise the body's natural healing potential. Since 2010, we have translated deep scientific expertise into clinically proven products for bone, nerve and tendon repair, enabling surgeons to improve outcomes and restore patient mobility, enhancing healing and quality of life for more than 75,000 patients worldwide.

3:30PM AVITA MEDICAL (AVH)


AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies RECELL, Cohealyx and PermeaDerm are designed to optimize wound healing, effectively accelerating the time to patient recovery.

4:00PM POLYNOVO (PNV)

PolyNovo develops innovative medical devices utilising the patented bioabsorbable polymer technology NovoSorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways.

4:30PM AROA BIOSURGERY (ARX)

Aroa Biosurgery is a global medical device company committed to unlocking regenerative healing for everybody through its AROA ECM™ complex wound and tissue reconstruction products. The AROA ECM technology platform is a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people in New Zealand and North America.



Day 3: Thursday 19 November

8:30AM LTR PHARMA (LTP)

LTR Pharma Ltd is a biotechnology company developing and commercialising rapid-acting intranasal therapies. LTR is preparing to launch ROXUS in the U.S. through the 503A pathway, while advancing SPONTAN® for erectile dysfunction and its broader intranasal platform targeting significant global healthcare markets.

9:00AM NEURIZON THERAPEUTICS (NUZ)


Neurizon Therapeutics is a late clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases by targeting impaired cellular protein clearance pathways. Its lead candidate, NUZ-001, is in the Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in Q2 2027. The company combines differentiated science, clinical execution and commercial readiness.

9:30AM MESOBLAST (MSB)

Mesoblast is a global leader in allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its Ryoncil® is the first FDA-approved mesenchymal stromal cell (MSC) therapy for paediatric SR-aGvHD. The company is advancing additional cell therapies targeting adult SR-aGvHD, heart failure and chronic low back pain.

10:00AM NYRADA (NYR)

Nyrada Inc. is a clinical-stage biotechnology company developing small-molecule therapies targeting TRPC ion channels. Its lead candidate, Xolatryp®, has demonstrated preclinical cardioprotective and neuroprotective efficacy and completed Phase I. A Phase IIa trial is underway evaluating Xolatryp for reducing myocardial ischemia-reperfusion injury in STEMI patients undergoing PCI.



Day 3: Thursday 19 November

10:30AM DOCTOR CARE ANYWHERE (DOC)

Doctor Care Anywhere Group Plc is one of the UK's largest private providers of telehealth services. The Company connects patients to virtual GP consultations, mental health, physiotherapy, health assessment and weight management services on its proprietary platform, working with insurers, healthcare providers and corporate customers and directly with consumers.

11:00AM PYC THERAPEUTICS (PYC)

PPYC Therapeutics is a precision medicine company developing a new generation of RNA therapeutics for patients with genetic diseases who currently have no treatment options. By targeting the underlying causes of disease, PYC aims to deliver transformative treatments and improve outcomes for underserved patient populations worldwide.

11:30AM NEUREN (NEU)


Neuren Pharmaceuticals develops therapies for serious neurological disorders. DAYBUE® (trofinetide), licensed worldwide to Acadia Pharmaceuticals, is approved in the US, EU, Canada and Israel for Rett syndrome. NNZ-2591 (ercanetide) is in clinical development for multiple neurodevelopmental disorders, and now in the Phase 3 "Koala" trial for children with Phelan-McDermid syndrome.

12:00PM ALTERITY THERAPEUTICS (ATH)

Alterity Therapeutics is a clinical-stage biotech developing ATH434, an iron chaperone, for Multiple System Atrophy, a progressive neurodegenerative disease with no approved disease-modifying therapy. ATH434 holds FDA Fast Track and Orphan Drug designations. Following its End-of-Phase 2 meeting with the FDA, Alterity is preparing a single pivotal Phase 3 trial.

12:30PM ONCOSIL MEDICAL (OSL)

OncoSil Medical is an Australian medical device company commercializing targeted internal radiation therapies. Its flagship device, OncoSil™, treats advanced, unresectable pancreatic cancer alongside chemotherapy. Already approved in over 30 countries, this breakthrough technology addresses a massive US$4.2 billion global market opportunity with no direct competition.



Day 3: Thursday 19 November

1:00PM AMPLIA THERAPEUTICS (ATX)

Amplia Therapeutics is a clinical-stage oncology company developing narmafotinib, a novel oral FAK inhibitor. Following promising results from the ACCENT pancreatic cancer trial, the Company is preparing for a registrational study, and in addition has partnered with Eli Lilly to explore a combination strategy with olomorasib in lung cancer.

1:30PM RACURA ONCOLOGY (RAC)


Racura is developing RC220 a drug that was recently found to switch off a key cancer gene, MYC, which is upregulated in 70% of all cancers but is considered to be 'undruggable'. Racura has three clinical programs including a Phase 3 study in acute myeloid leukemia (AML), a highly MYC-dependent disease.

2:00PM SYNTARA (SNT)

Syntara is a clinical-stage drug development company targeting fibrosis and inflammation. Its lead asset, amsulostat, has a competitive profile in myelofibrosis and an FDA agreed clinical development pathway. Pipeline drugs in skin scarring and Parkinson's disease have clinical proof of concept and drive significant news flow in the year ahead.

2:30PM IMMUTEP (IMM)

Immutep is a pioneer in developing therapeutics designed to stimulate or suppress the immune system to fight cancer and autoimmune diseases. This history of innovation stems from its Chief Scientific Officer Dr. Frédéric Triebel's discovery of Lymphocyte Activation Gene-3 (LAG-3) and his subsequent research elucidating paths to improve clinical responses for patients by harnessing the power of their own immune systems.



Day 3: Thursday 19 November

3:00PM IMMVIRX

ImmVirX is developing targeted RNA oncolytic immunotherapies for cancer patients with advanced/metastatic disease and limited treatment options. Our lead asset, IVX037, is currently advancing in Phase 1b clinical studies, and our second candidate, IVX055, is expected to enter the clinic in early 2027.

3:30PM QBIOTICS GROUP

QBiotics Group is an Australian clinical-stage biotechnology company developing innovative oncology and wound-healing therapies from its proprietary epoxitiglianes platform. Its lead asset, tigilanol tiglate, has demonstrated compelling Phase II cancer trial results, while EBC-1013, a topical hydrogel for chronic wounds, is currently being evaluated in a Phase I clinical trial.

4:00PM MAYNE PHARMA GROUP (MYX)

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel medicines that are safer and more accessible for patients. With over 40 years of innovation in oral drug delivery technologies, the company develops complex pharmaceutical products and supports global operations through its technology-driven expertise and workforce.

4:30PM BLS PHARMACEUTICALS (BLS)

BLS Pharmaceuticals Ltd is an international healthcare, life sciences and novel medicines development and manufacturing company with operations in Australia (head office), United Kingdom, Germany, and the United States serving customers world-wide.